Regenacy Pharmaceuticals
Biotechnology, 303 Wyman St, Waltham, , 2451, Massachusetts, United States, 1-10 Employees
Phone Number: 61********
Who is REGENACY PHARMACEUTICALS
Regenacy Pharmaceuticals is developing a novel, disease-modifying approach to treating peripheral neuropathies that goes beyond pain and symptom management to restore peripheral nerve fun...
Read More
-
Headquarters: 303 Wyman St, Waltham, Massachusetts, 2451, United States
-
Date Founded: 2016
-
Employees: 1-10
-
Revenue: Under $1 Million
-
Active Tech Stack: See technologies
-
CEO:
Simon Jones
Email
Phone
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from REGENACY PHARMACEUTICALS
Regenacy Pharmaceuticals Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Regenacy Pharmaceuticals
Answer: Regenacy Pharmaceuticals's headquarters are located at 303 Wyman St, Waltham, , 2451, Massachusetts, United States
Answer: Regenacy Pharmaceuticals's phone number is 61********
Answer: Regenacy Pharmaceuticals's official website is https://regenacy.com
Answer: Regenacy Pharmaceuticals's revenue is Under $1 Million
Answer: Regenacy Pharmaceuticals's SIC: 2834
Answer: Regenacy Pharmaceuticals's NAICS: 325412
Answer: Regenacy Pharmaceuticals has 1-10 employees
Answer: Regenacy Pharmaceuticals is in Biotechnology
Answer: Regenacy Pharmaceuticals contact info: Phone number: 61******** Website: https://regenacy.com
Answer: Regenacy Pharmaceuticals is developing a novel, disease-modifying approach to treating peripheral neuropathies that goes beyond pain and symptom management to restore peripheral nerve function. Our lead compound ricolinostat (ACY-1215) is an oral, selective inhibitor of the microtubule modifying enzyme HDAC6 with first-in-class potential, currently positioned to enter Phase 2 clinical trials. Our investigation of ricolinostat for diabetic, chemotherapy-induced and inherited peripheral neuropathies is based on compelling proof-of-concept preclinical studies demonstrating restoration of normal nerve function. We were founded in December 2016 following the acquisition of Acetylon Pharmaceuticals by Celgene. Regenacy received exclusive rights to ricolinostat, a clinical stage, orally bioavailable, HDAC6 selective inhibitor, for a range of non-cancer disease indications. We also have a unique and proprietary portfolio of selective HDAC1,2 inhibitors with potential for treating cancer, hemoglobinopathies, and cognitive dysfunction.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month